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1)
Introduction
Renal dysfunction in chronic liver disease is charac-
terized by impaired natriuresis, decreased free water clear-
ance, and decreased glomerular filtration rate (GFR).
Hyponatremia, ascites, and hepatorenal syndrome (HRS)
represent the clinical consequences of disturbances in renal
function. Optimal management of renal dysfunction in cir-
rhosis is extremely important in that renal dysfunction fre-
quently complicates the clinical course of advanced liver
disease and is invariably associated with poor clinical
outcomes. Hyponatremia is present in about 50% of pa-
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tients with cirrhosis and is associated with increased rate
of other complications such as gastrointestinal bleeding,
spontaneous bacterial peritonitis, and hepatic encephalop-
athy
1). The presence of ascites predicts poor clinical out-
come in cirrhotic patients, as shown by the 3-year survival
rate for patients with ascites at 50%
2). Progressive liver
failure and superimposition of precipitating events culmi-
nate in the development of HRS, a state of severe intrarenal
vasoconstriction and reduced GFR without intrinsic renal
damage. Survival of patients with liver disease continues
to be affected by the presence of renal dysfunction, even
after they underwent liver transplantation
3).
Renal dysfunction in cirrhosis is a clinical consequence
of peripheral arterial vasodilatation and hyperdynamic cir-
culation caused by portal hypertension. Clinical ob-
servations and recent experimental studies have shed light
on the pathogenesis of hyperdynamic circulation in chronic
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Renal dysfunction in patients with chronic liver disease encompasses a clinical spectrum of hyponatremia,
ascites, and hepatorenal syndrome. Clinical observation has suggested that patients with cirrhosis have hyper-
dynamic circulation, and recent studies strongly suggest that peripheral arterial vasodilatation and subsequent
development of hyperdynamic circulation are responsible for disturbances in renal function. Arterial vaso-
dilatation predominantly occurs in the splanchnic vascular bed, and seems to precede an increase in blood
flow in the splanchnic circulation. Nitric oxide plays a central role in progressive vasodilatation, as evidenced
by in vivo and in vitro studies. Renal dysfunction negatively affects the prognosis of patients with cirrhosis,
as hyponatremia, ascites, and azotemia are associated with increased rate of complications and mortality.
Recent advances in understanding the pathophysiology of renal dysfunction have enabled clinicians to devel-
op new diagnostic criteria and therapeutic recommendations. Hepatorenal syndrome is regarded as a poten-
tially reversible disorder, as systemic vasoconstrictors with concomitant albumin administration are emerging
as a promising management option, especially in terms of providing bridging therapy for patients awaiting
liver transplantation.
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liver disease. Better understanding of the pathophysiology
enabled clinicians to introduce effective therapies for renal
dysfunction once considered irreversible or medically in-
tractable, and led to the proposal of new concepts and diag-
nostic criteria for HRS
4).
Pathophysiology of renal dysfunction in
chronic liver disease
1. Peripheral arterial vasodilatation and hyperdy-
namic circulation in chronic liver disease
Portal hypertension in cirrhosis is one of the best exam-
ples of hyperdynamic circulation, which results from a
combination of increased cardiac output and dilated periph-
eral vascular bed
5). Investigators have been aware of the
importance of primary vasodilatation in cirrhosis for a long
time, and bedside observation made by astute clinicians
describes the typical features of hyperdynamic circulation
in patients with cirrhosis, including increased pulse pres-
sure, warm extremities, and capillary pulsations in the nail
bed. Based on these findings, Kowalski and Abelmann
were the first to demonstrate an increase in cardiac output
and a decrease in peripheral vascular resistance in a patient
with alcoholic cirrhosis
6). A subsequent study corroborated
this finding
7). In addition, a host of studies using Doppler
ultrasonography to assess blood flow in various organs in
patients with cirrhosis have demonstrated (1) the state of
hyperdynamic circulation in chronic liver disease, (2) pre-
dominant vasodilatation in the splanchnic vessels, and (3)
relative vasoconstriction in other organs such as the kid-
neys
8, 9).
Splanchnic and systemic vasodilatation in the wake of
portal hypertension creates a state of relative hypovolemia,
which activates sodium-conserving mechanisms and leads
to an increase in plasma volume. Most of the increase in
plasma volume is used to fill up the increased splanchnic
vascular compartment. Meanwhile, portal blood flow in-
creases in the face of increased intrahepatic vascular resist-
ance, as portosystemic collaterals partially decompress the
portal vein and provides conduits for pooled splanchnic
blood. The importance of increased blood flow in the portal
vein was shown in a previous study, which reports that
an increase in portal venous flow is a major contributing
factor in maintaining and aggravating portal hypertension
in conditions of increased intrahepatic resistance
10).
2. Alterations in renal function
Splanchnic and systemic vasodilatation leads to renal
vasoconstriction and impaired renal function (Fig. 1).
Relative hypovolemia activates the sympathetic nervous
system and renin-angiotensin-aldosterone system, and in-
creases nonosmotic secretion of arginine vasopressin
(AVP), resulting in sodium and water retention and devel-
opment of ascites and hyponatremia. Renal hypoperfusion
and cardiac dysfunction combine to provoke severe intra-
renal vasoconstriction leading to HRS.
The clinical course of renal impairment in cirrhosis is
Fig. 1. Pathogenesis of renal dysfunction in chronic liver disease. RAAS, renin-angiotensin-
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further complicated by progressive cardiac dysfunction. As
a result of peripheral vasodilatation and retention of so-
dium and water, cardiac output increases in the early phase
of chronic liver disease. However, this increase in cardiac
output fails to meet the need of the body and results in
high-output cardiac failure. As peripheral vasodilatation
continues to progress, myocardial contractility and cardiac
output begin to decrease and low-output cardiac failure en-
sues
11). Reduced cardiac output decreases renal perfusion
and may precipitate the development of HRS, as renal hy-
poperfusion seems to trigger severe intrarenal vaso-
constriction
12).
3. Pathogenesis of splanchnic arterial vasodilatation
In vivo and in vitro studies have investigated the mecha-
nisms of splanchnic vasodilatation in chronic liver disease
by using experimental animal models for cirrhosis. Major
findings from these studies are as follows: (1) the source
of vascular hyporeactivity to vasoconstricting stimuli lies
in the vascular endothelium
13); (2) endothelial and neuronal
isoforms of nitric oxide synthase (eNOS and nNOS, re-
spectively) are upregulated in the splanchnic circulation
14);
(3) cirrhotic animals are remarkably sensitive to the effect
of nonspecific inhibition of nitric oxide (NO) synthesis as
compared with normal controls
15); (4) and inhibition of NO
synthesis almost completely normalize major hemody-
namic abnormalities and renal function
16, 17). Vascular hy-
poresponsiveness and increased NO production were ob-
served in major systemic arteries as well as in splanchnic
arteries
18, 19).
Nitric oxide is believed to be a key player in patho-
genesis of splanchnic and systemic vasodilatation in chron-
ic liver disease. Portal hypertension activates eNOS and
nNOS in the splanchnic circulation through a myriad of
putative mechanisms, including increased shear stress on
the mesenteric arterial wall, increased expression of vas-
cular endothelial growth factor (VEGF) in the splanchnic
microcirculation, overproduction of inflammatory cyto-
kines (e.g., tumor necrosis factor), and bacterial trans-
location (Fig. 2). Upregulation of NO synthases is not like-
ly to be induced by increased mesenteric blood flow, as
the time-course of NO production has shown that over-
production of NO occurs before the blood flow increases
in the superior mesenteric artery
20). Rather, other signals
located upstream of NO, such as cyclic stress in the mesen-
teric arterial wall or increased expression of VEGF, seem
to be involved in the enhanced eNOS activity. Additional
studies lend support to the role of VEGF in splanchnic
vasodilatation by showing that inhibition of VEGF receptor
effectively attenuates splanchnic vasodilatation
21, 22).
Fig. 2. Pathogenesis of hyperdynamic circulation in cirrhosis. VEGF, vascular endothelial
growth factor; NOS, nitric oxide synthase; NO, nitric oxide; EABV, effective arterial blood
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Increased NO production leads to splanchnic and sys-
temic arterial vasodilatation, which, combined with in-
creased effective arterial blood volume, increases blood
flow and augments NO production, as an increase in blood
flow is a well-known stimulus for NO synthases (Fig. 2).
As mentioned before, portosystemic shunts have a sig-
nificant role in maintaining or aggravating hyperdynamic
circulation, and increased portal blood flow can enhance
the production of NO in the splanchnic circulation. Circu-
lating hormones (e.g., endocannabinoids), gastrointestinal
hormones (e.g., glucagon), and proinflammatory cytokines
(e.g., tumor necrosis factor-alpha) induced by bacterial
translocation can contribute to increased NO produc-
tion
23-25).
There are NO-independent mechanisms involved in hy-
perdynamic circulation in cirrhosis, as knockout of eNOS
did not completely prevent the development of hyper-
dynamic circulation in portal hypertension
26). Studies on
impaired reactivity of the endothelium to vasoconstrictors
in cirrhotic animals have reported reduction in phosphor-
ylation of the myosin light chain (MLC) of the vascular
smooth muscle cell (VSMC). Contractile agonists usually
stimulate MLC phosphorylation via the activation of MLC
kinase or the inhibition of MLC phosphatase. Phosphory-
lated MLC in turn activates actin-myosin ATPase, thereby
crosslinking actin-myosin to induce smooth muscle con-
traction. Vasoconstrictors such as epinephrine and vaso-
pressin bind to their respective receptors on the surface
of the VSMC and activate phospholipase C (PLC), which
produces inositol triphosphate (IP3) and diacylglycerol
(DAG). IP3 mobilizes calcium from the sarcoplasmic retic-
ulum, and DAG activates protein kinase C which is in-
volved in the increased activity of MLC kinase. In addi-
tion, receptor activation leads to increased activity of rho
kinase, which is believed to inhibit the activity of MLC
phosphatase. As a result, increased MLC phosphorylation
and increased intracellular calcium concentration leads to
smooth muscle contraction.
Reported alterations in PLC and rho kinase signaling
in cirrhotic animals include decreased activation of PLC;
subsequently diminished production of IP3 and DAG; re-
duced activity of DAG-dependent protein kinase C; and
reduced rhoA activity
27-29).
Clinical manifestations
Hyponatremia, ascites, and HRS are among the principal
clinical consequences of the progressive arterial vaso-
dilatation and hyperdynamic circulation in cirrhosis.
Impaired sodium excretion and free water clearance result
in the development of hyponatremia and ascites, and pro-
gressive decrease in GFR results in the development of
HRS.
Progression of renal dysfunction in cirrhosis can be div-
ided into five stages (Table 1)
30). In the early phase of
liver dysfunction (stage 1), patients can excrete daily so-
dium intake, though just in the range of normal daily so-
dium intake, and show normal GFR and absence of ascites.
In the next phase of renal dysfunction (stage 2), impaired
Table 1. Stages of Renal Dysfunction in Chronic Liver Disease
Stages Description Na
+ metabolism Free water clearance GFR
1 Compensated cirrhosis Normal just in the limit of Normal Normal
regular Na
+ intake
2 Renal Na
+ retention Unable to excrete regular Normal Normal; circulatory
without neurohormonal Na
+ intake; dysfunction may exist
activation Urine Na
+ 50-90 mEq/d
3 Neurohormonal activation Impaired; Impaired; Normal or
Urine Na
+ <10 mEq/d Mild hyponatremia modestly educed
4 Type 2 HRS Urine Na
+ <10 mEq/d; Hyponatremia Moderate GFR↓
Refractory ascites
5 Type 1 HRS Urine Na
+ <10 mEq/d; Hyponatremia Severe GFR↓
Refractory ascites
GFR, glomerular filtration rate; HRS, hepatorenal syndrome.46 Electrolyte Blood Press 7:42-50, 2009
natriuresis takes place without overt activation of neuro-
hormonal systems, as patients cannot mount an adequate
natriuretic response to exogenous sodium load while con-
centrations of plasma catecholamine, aldosterone or AVP
remain within the normal range. Increased expression of
renal sodium transporters in the distal tubule seems to be
involved in this phenomenon
31). Subtle unidentified circu-
latory dysfunction also may play a role. As liver function
deteriorates (stage 3), overt activation of neurohormonal
systems occurs, and ascites and hyponatremia develop. In
the final stages of cirrhosis, severe vasodilatation and renal
vasoconstriction lead to refractory ascites and HRS. Type
2 HRS (stage 4) is considered to be a mild, slowly pro-
gressive form of renal failure, and type 1 HRS (stage 5)
is characterized by rapidly worsening renal function, re-
fractory ascites, and severe sodium retention.
Hyponatremia is associated in a graded fashion with oth-
er serious complications of liver cirrhosis. As compared
with patients with mild hyponatremia (plasma sodium
131-135 mEq/L), patients with moderate-to-severe hypona-
tremia (plasma sodium 130 mEq/L) have significantly
higher risk of developing hepatic encephalopathy, sponta-
neous bacterial peritonitis, and gastrointestinal bleeding
1).
The most common precipitating factor for hyponatremia
is inappropriate use of diuretics, especially for patients with
ascites but without peripheral edema. As the peritoneum
has limited capacity for mobilizing ascitic fluid (~500
mL/day), excessive diuresis can reduce intravascular vol-
ume and renal free water clearance, leading to development
of hyponatremia.
Ascites develops as a result of sodium retention by the
kidney and disruption of the Starling equilibrium in the
splanchnic circulation. As mentioned earlier, activation of
the sympathetic nervous system, renin-angiotensin-aldo-
sterone axis, and nonosmotic AVP secretion leads to so-
dium and water retention by the kidney. Increased hydro-
static pressure and decreased oncotic pressure in the capil-
lary of the bowel, which occur as a result of portal hyper-
tension, increases hepatic lymph production.
HRS is caused by severe renal vasoconstriction which
occurs in patients with advanced liver disease and circu-
latory dysfunction. By definition, HRS is not associated
with intrinsic renal disease or nephrotoxic injury, as kid-
neys from patients with HRS function perfectly when
transplanted to other patients. HRS may occur sponta-
neously, but is frequently precipitated by bacterial in-
fections such as spontaneous bacterial peritonitis (SBP),
gastrointestinal bleeding, or inadequate albumin replace-
ment after therapeutic paracentesis. These precipitating
events abruptly reduce renal perfusion, thereby tipping the
balance toward vasoconstriction between intrarenal vaso-
dilators such as prostaglandins and vasoconstrictors. Imbal-
ance between vasoactive mediators within the kidney fur-
ther diminishes renal blood flow and causes HRS.
The diagnosis of HRS is based upon documentation of
progressive renal failure and exclusion of intrinsic struc-
tural renal damage and other systemic illness affecting re-
nal function. Type 1 HRS is a severe, rapidly progressive
type of renal failure (i.e. doubling of serum creatinine to
a level greater than 2.5 mg/dL in less than 2 weeks), while
type 2 HRS represents moderate, slowly progressive renal
failure (i.e. serum creatinine 1.5-2.5 mg/dL). Since the first
proposal of diagnostic criteria in 1994
32), new concepts
have emerged from experimental and clinical studies: (1)
peripheral arterial vasodilatation predominantly occurs in
the splanchnic vascular bed; (2) cardiac output in patients
with HRS is insufficient for the patient’s needs; (3) devel-
opment of type 1 HRS is often triggered by other super-
imposing factors, most commonly spontaneous bacterial
peritonitis or gastrointestinal bleeding; (4) renal function
can be improved by medical treatment in patients with
HRS
4). As compared with the diagnostic criteria in 1994,
new diagnostic criteria proposed in 2007 (1) eliminated
the additional criteria as they are not essential for diag-
nosis; (2) recommended that plasma volume expansion
should be performed with albumin rather than saline; (3)
excluded creatinine clearance as it is impractical and diffi-
cult to interpret in chronic liver disease; (4) suggested that
renal failure in the setting of ongoing bacterial infection
should be considered as HRS, emphasizing that effective
therapy should be started before the resolution of bacterial
infection
4).JW Lee : Renal Dysfunction in Patients with Chronic Liver Disease 47
Management
1. Hyponatremia
Restriction of free water intake is the mainstay of treat-
ment for hyponatremia. Severe symptomatic hyponatremia
should be managed with hypertonic saline infusion.
However, both treatments are not aimed to address the un-
derlying pathophysiology of water retention, the non-
osmotic AVP secretion.
Pharmacologic inhibition of AVP action is emerging as
a valuable addition to the armamentarium for management
of hypervolemic or euvolemic hyponatremia. Binding to
V2 receptor on the basolateral surface of the collecting tub-
ular epithelial cells, V2 receptor antagonists (vaptans) in-
hibit the action of AVP and increase free water clearance.
Several studies on cirrhotic patients with ascites and hypo-
natremia showed that V2 receptor antagonists increased uri-
nary excretion of free water and plasma sodium concen-
tration and were not associated with increased rates of seri-
ous adverse events
33-35). A multi-center, randomized, place-
bo-controlled trial on 110 patients with ascites and hypona-
tremia reported that satavaptan improved the control of as-
cites, moderately increased plasma sodium concentration,
and was not associated with significant alterations in plas-
ma and urine electrolyte concentrations
33). Patients who
start on V2 receptor antagonists may require admission, as
clinical trials with tolvaptan showed that a small fraction
of patients (~2%) had early-stage increases in plasma so-
dium concentration higher than the acceptable range
35).
2. Ascites
To counterbalance sodium retention in cirrhosis, neg-
ative sodium balance should be achieved by reducing daily
sodium intake to less than 2 g/d and by starting diuretic
therapy. Sodium restriction should be maintained through-
out the entire course of ascites management. Mineralocorti-
coid antagonists are the first-line diuretics in management
of ascites, as secondary hyperaldosteronism has been con-
sidered important in the pathogenesis of ascites. Loop diu-
retics and thiazide may be added if natriuresis is insuffi-
cient. As excessive natriuresis can greatly reduce intra-
vascular volume and precipitate acute renal failure, caution
should be exercised especially for patients with ascites in
the absence of peripheral edema. Refractory ascites should
be managed with therapeutic paracentesis with albumin re-
placement, construction of peritoneovenous shunt, or trans-
hepatic intrajugular portosystemic shunt (TIPS).
3. Hepatorenal syndrome
An ideal treatment for HRS should be aimed at improv-
ing renal perfusion and glomerular filtration rate. It should
achieve (1) reduction of serum creatinine to less than 1.5
mg/dL, (2) prolongation of survival, and (3) avoidance of
serious adverse effects. Despite remarkable advances in the
understanding of the pathophysiology of HRS, no ideal
medical therapy has been discovered so far.
Liver transplantation is the only treatment proven to pro-
long survival in patients with HRS. It is important, how-
ever, to provide adequate management aimed at reversal
of azotemia, because preoperative azotemia negatively af-
fects the prognosis of the patients who underwent liver
transplantation, and because effective treatment for HRS
can earn valuable time for patients who await liver trans-
plantation
3).
Given the central role of splanchnic vasodilatation and
hyperdynamic circulation in the development of renal dys-
function, new medical therapies are designed to reduce in-
tense arterial vasodilatation and to expand the effective cir-
culating volume. Systemic vasoconstrictor therapies, com-
bined with albumin infusion, were found to be effective
in patients with HRS in reversing renal dysfunction, and
the survival of the patients who recovered from their renal
dysfunction was significantly improved
36-39). The available
vasoconstrictors proven to be effective in clinical trials are
vasopressin analogues (e.g., terlipressin, ornipressin)
36, 37),
midodrine plus octreotide
38), and norepinephrine
39). Com-
plications such as myocardial infarction, cerebrovascular
disease or hypertension may preclude the use of vaso-
constrictors. Concomitant volume expansion with intra-
venous albumin is essential, as vasoconstrictor therapy
without albumin produced little effect in reversing azote-
mia
40). An international group of experts issued treatment48 Electrolyte Blood Press 7:42-50, 2009
recommendations for the management of type 1 HRS
4).
TIPS may be considered as a therapeutic option for
HRS, especially when the risk of hepatic encephalopathy
is low. Unfortunately, most patients with HRS are too ill
to undergo TIPS. The Model for End-stage Liver Disease
(MELD) score, a scoring system developed to predict the
survival of patients with chronic liver disease and to priori-
tize organ allocation to patients in more critical condition,
can be used to predict the survival of patients who under-
went TIPS. A computational model suggested that TIPS
should not be recommended for patients with a MELD
score >18, as their median survival would be less than
3 months
41).
Renal replacement therapies should be considered when
patients are awaiting a liver transplant or when there is
the possibility of improvement in liver function. In one
retrospective study, 30 percent of patients who required
dialysis survived to liver transplantation
42). Patients with
an acute and potentially reversible liver dysfunction may
benefit from renal replacement therapy until they recover
their liver function. Management of HRS is summarized
in Table 2.
4. Prevention of HRS
Two studies have evaluated the efficacy of preventive
measures for HRS. Sort et al. reported that intravenous
albumin infusion combined with antibiotics for patients
with SBP was associated with reduced rate of impaired
renal function and increased survival, as compared with
antibiotics alone
43). Intravascular volume expansion might
have been helpful to reverse the progression of renal dys-
function in patients with SBP, as bacterial translocation
and increased inflammatory cytokines might augment nitric
oxide production through the putative tetrahydrobiopterin
synthesis pathway.
A randomized trial reported significant benefits with the
administration of norfloxacin at 400 mg/day to patients
with cirrhosis who met the following criteria: (a) ascites
fluid total protein <1.5 g/dL and either of the following:
(b) a Child-Pugh score ≥9 points and serum bilirubin
3 mg/dL; or (c) serum creatinine 1.2 mg/dL, blood urea
nitrogen 25 mg/dL, or serum sodium 130 mEq/L
44).
Norfloxacin was associated with decreased one-year proba-
bility of SBP and HRS, and improved 3-month survival.
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